AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34846602 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier dietary pattern characterized by consumption of vegetables and rye bread
Number of subjects: 351
Study 34846602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory diet (higher E-DII score)
Number of subjects: 351
Study 34846602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient intakes (total fat, saturated fatty acids, trans fatty acids)
Number of subjects: 351
Study 34846614 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci R-TME
Number of subjects: 134
Study 34846614 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro Hand S R-TME
Number of subjects: 134
Study 34846614 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic TME (L-TME)
Number of subjects: 134
Study 34846636 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 34847232 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients treated with intensive chemotherapy
Number of subjects: 1725
Study 34847232 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with NPM1 mutations
Number of subjects: 1725
Study 34847232 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with mutations in the N-terminal SH2 domain
Number of subjects: 1725
Study 34847232 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with inv(3)(q21q26)/t(3;3)(q21;q26) and a normal karyotype
Number of subjects: 1725
Study 34847232 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN11 mutations in patients with typical complex karyotype and core-binding factor AML
Number of subjects: 1725
Study 34847547 — intervention group
Group type: EXPERIMENTAL
Intervention: Utah intracortical multi-electrode arrays
Number of subjects: 0
Study 34847615 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of depression (FHD)
Number of subjects: 129
Study 34848513 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIOUS-01 (PLGA-based immunomodulatory nanoparticles)
Number of subjects: 15
Study 34848514 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 56
Study 34848514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power diode laser
Number of subjects: 56
Study 34848517 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training program targeting inhibitory skills
Number of subjects: 200
Study 34848517 — intervention group
Group type: COMPARATOR
Intervention: Computerised neutral sensorial program (active control)
Number of subjects: 200
Study 34848522 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 mL/d of orange juice (OJ)
Number of subjects: 42
Study 34848522 — intervention group
Group type: COMPARATOR
Intervention: Control drinks with and without hesperidin (approx. 200-215 mg)
Number of subjects: 42
Study 34848527 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) therapy
Number of subjects: 0
Study 34848527 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (not specified)
Number of subjects: 0
Study 34848527 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (not specified)
Number of subjects: 0
Study 34848515 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diagnosis of SARS-CoV-2
Number of subjects: 1063
Study 34848515 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1063
Study 34848515 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >80 years
Number of subjects: 1063
Study 34848515 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diagnosis of dementia
Number of subjects: 1063
Study 34848515 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney disease
Number of subjects: 1063
Study 34848515 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 1063
Study 34848515 — intervention group
Group type: COMPARATOR
Intervention: Increase to delay in surgery
Number of subjects: 1063
Study 34848515 — intervention group
Group type: COMPARATOR
Intervention: Type of anaesthetic given
Number of subjects: 1063
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian/Asian British ethnicity
Number of subjects: 15227
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Household overcrowding
Number of subjects: 15227
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Any visits to/from other households in previous week
Number of subjects: 15227
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of visits to indoor public places
Number of subjects: 15227
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline occupation excluding health/social care
Number of subjects: 15227
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised body mass index (BMI) 25.0-30.0 kg/m²
Number of subjects: 15227
Study 34848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic disease
Number of subjects: 15227
Study 34848750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 3 sessions of 30-min treadmill plus 2 sessions of 30-min strength training per week for 12 weeks
Number of subjects: 18
Study 34848750 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 18
Study 34848836 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density (HED) food sensitization
Number of subjects: 201
Study 34848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy density (LED) food sensitization
Number of subjects: 201
Study 34848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between HED and LED food sensitization
Number of subjects: 201
Study 34848836 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting (DD) moderation
Number of subjects: 201
Study 34848949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 60
Study 34848949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34849303 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressor nebulization
Number of subjects: 15
Study 34849303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulization
Number of subjects: 15
Study 34849303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh nebulization
Number of subjects: 15
Study 34849638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccinated (Boostrix®) mothers' infants
Number of subjects: 79
Study 34849666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericarditis
Number of subjects: 2533
Study 34849666 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopericarditis
Number of subjects: 2533
Study 34849666 — intervention group
Group type: COMPARATOR
Intervention: NSTEMI
Number of subjects: 2533
Study 34849677 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentrations ≥ median (17 ng/L)
Number of subjects: 170
Study 34849677 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentrations
Number of subjects: 170
Study 34849728 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (starting dose 300 mg b.i.d.)
Number of subjects: 134
Study 34849728 — intervention group
Group type: COMPARATOR
Intervention: Control (historical cohort of untreated patients)
Number of subjects: 134
Study 34849989 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 12 months
Number of subjects: 32
Study 34849989 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 24 months
Number of subjects: 32
Study 34850014 — intervention group
Group type: EXPERIMENTAL
Intervention: ECL-GADA positivity
Number of subjects: 602
Study 34850014 — intervention group
Group type: EXPERIMENTAL
Intervention: ECL-GADA z-score titers
Number of subjects: 602
Study 34850014 — intervention group
Group type: EXPERIMENTAL
Intervention: ECL-IAA positivity
Number of subjects: 602
Study 34850014 — intervention group
Group type: EXPERIMENTAL
Intervention: RBA-GADA positivity
Number of subjects: 602
Study 34850014 — intervention group
Group type: COMPARATOR
Intervention: RBA-IAA positivity
Number of subjects: 602
Study 34850024 — intervention group
Group type: EXPERIMENTAL
Intervention: 4T cohort (Teamwork, Targets, Technology and Tight Control)
Number of subjects: 135
Study 34850024 — intervention group
Group type: EXPERIMENTAL
Intervention: 4T cohort with remote monitoring
Number of subjects: 135
Study 34850024 — intervention group
Group type: EXPERIMENTAL
Intervention: 4T cohort
Number of subjects: 135
Study 34850052 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HEI >57
Number of subjects: 108
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) and VDX (10 mg)
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) and VDX (10 mg)
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) and VDX (20 mg)
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (all doses) and VDX (all doses)
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and VDX
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: VDX
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 gene therapy
Number of subjects: 21
Study 34850166 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment biopsies
Number of subjects: 21
Study 34850167 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 33
Study 34850325 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-specific TCR redirected T (HBV-TCR-T) cells
Number of subjects: 8
Study 34850380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic treatment
Number of subjects: 980
Study 34850380 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 980
Study 34850380 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 980
Study 34850616 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-hGH on iSYS
Number of subjects: 39
Study 34850616 — intervention group
Group type: EXPERIMENTAL
Intervention: LIAISON-hGH on Liaison XL
Number of subjects: 39
Study 34850616 — intervention group
Group type: EXPERIMENTAL
Intervention: Elecsys ROCHE-hGH on COBAS 8000
Number of subjects: 39
Study 34850616 — intervention group
Group type: COMPARATOR
Intervention: Elecsys Roche-hGH method
Number of subjects: 39
Study 34850742 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 envelope (Env) plasmid DNA prime and recombinant modified vaccinia virus Ankara (MVA) boost
Number of subjects: 20
Study 34850742 — intervention group
Group type: COMPARATOR
Intervention: Recombinant MVA expressing a heterologous Env
Number of subjects: 20
Study 34850966 — intervention group
Group type: EXPERIMENTAL
Intervention: SNOT-22 rhinologic symptoms domain
Number of subjects: 0
Study 34851726 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Number of subjects: 167
Study 34852172 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX168
Number of subjects: 0
Study 34852172 — intervention group
Group type: EXPERIMENTAL
Intervention: C5a/C5aR1 blockade
Number of subjects: 0
Study 34852172 — intervention group
Group type: EXPERIMENTAL
Intervention: C5a/C5aR1
Number of subjects: 0
Study 34852175 — intervention group
Group type: EXPERIMENTAL
Intervention: AD disease
Number of subjects: 231
Study 34852175 — intervention group
Group type: COMPARATOR
Intervention: AR/XLR and TINF2 disease
Number of subjects: 231
Study 34852175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 231
Study 34852305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity bridging chemotherapy (≥2 cycles)
Number of subjects: 0
Study 34852305 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity bridging chemotherapy (1 cycle)
Number of subjects: 0
Study 34852305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging chemotherapy (both intensities)
Number of subjects: 0
Study 34852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia training group (HT)
Number of subjects: 54
Study 34852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia training group (NT)
Number of subjects: 54
Study 34852758 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 54
Study 34852837 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tau PET imaging
Number of subjects: 67
Study 34852837 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal controls
Number of subjects: 67
Study 34853024 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives group (n=231)
Number of subjects: 460
Study 34853024 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=229)
Number of subjects: 460
Study 34853082 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised preventive treatment strategy (treating arteries instead of risk factors)
Number of subjects: 1391
Study 34853082 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque thickness
Number of subjects: 1391
Study 34853082 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male sex, greater plaque thickness, coronary heart disease, vascular surgery/stenting history, smoking
Number of subjects: 1391
Study 34853102 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656 (glucokinase activator)
Number of subjects: 150
Study 34853102 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo tablets
Number of subjects: 150
Study 34853114 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 60
Study 34853114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34853376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous access iohexol GFR measurement
Number of subjects: 31
Study 34853376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous access iohexol GFR measurement after blood discarding and saline flushing
Number of subjects: 31
Study 34853376 — intervention group
Group type: COMPARATOR
Intervention: Blood sampling from a second intravenous access
Number of subjects: 31
Study 34853430 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs associated with BPD risk at allele level (8 SNPs identified)
Number of subjects: 192
Study 34853430 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs4883955 on KLF12 and rs9953270 on CHST9
Number of subjects: 192
Study 34853430 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs on MBL2, NFKBIA, CEP170, MAGI2, and VEGFA genes
Number of subjects: 192
Study 34853430 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs on CHST9 and KLF12 genes
Number of subjects: 192
Study 34853430 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional relationship of genes harboring SNPs with WNT5A
Number of subjects: 192
Study 34853511 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory anti-diabetic medication (including metformin)
Number of subjects: 2222
Study 34853511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-containing therapy
Number of subjects: 2222
Study 34853511 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-diabetic medication (overall)
Number of subjects: 2222
Study 34853799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen and/or onasemnogene abeparvovec
Number of subjects: 103
Study 34853799 — intervention group
Group type: COMPARATOR
Intervention: Healthy control infants
Number of subjects: 103
Study 34853799 — intervention group
Group type: COMPARATOR
Intervention: Untreated SMA infants
Number of subjects: 103
Study 34853986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (POLARx™; Boston Scientific)
Number of subjects: 69
Study 34854079 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone (HD-DXM)
Number of subjects: 725
Study 34854079 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-DXM plus recombinant human thrombopoietin
Number of subjects: 725
Study 34854079 — intervention group
Group type: EXPERIMENTAL
Intervention: standard-dose rituximab
Number of subjects: 725
Study 34854079 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose rituximab
Number of subjects: 725
Study 34854315 — intervention group
Group type: EXPERIMENTAL
Intervention: QRSA+
Number of subjects: 130
Study 34854315 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA+
Number of subjects: 130
Study 34854315 — intervention group
Group type: EXPERIMENTAL
Intervention: QRSA+ and TWA+ together
Number of subjects: 130
Study 34854315 — intervention group
Group type: EXPERIMENTAL
Intervention: QRSA magnitude
Number of subjects: 130
Study 34854315 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD therapy
Number of subjects: 130
Study 34854418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rate at 3 L/min with HME attached
Number of subjects: 240
Study 34854418 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow rate at 6 L/min with HME attached
Number of subjects: 240
Study 34854418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rate at 3 L/min without HME
Number of subjects: 240
Study 34854418 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow rate at 6 L/min without HME
Number of subjects: 240
Study 34854418 — intervention group
Group type: EXPERIMENTAL
Intervention: HME (+) regardless of anesthetic agent
Number of subjects: 240
Study 34854418 — intervention group
Group type: COMPARATOR
Intervention: HME (-) regardless of anesthetic agent
Number of subjects: 240
Study 34854473 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 908
Study 34854473 — intervention group
Group type: COMPARATOR
Intervention: SCS + other intervention
Number of subjects: 908
Study 34854473 — intervention group
Group type: COMPARATOR
Intervention: SCS
Number of subjects: 908
Study 34854740 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered mesoporous silica (SiPore15)
Number of subjects: 0
Study 34854746 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-Guided Biopsy (MRGBx)
Number of subjects: 519
Study 34854790 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pneumonia
Number of subjects: 103
Study 34854790 — intervention group
Group type: COMPARATOR
Intervention: non-COVID-19 pneumonia
Number of subjects: 103
Study 34854816 — intervention group
Group type: EXPERIMENTAL
Intervention: how2trak postoperative monitoring
Number of subjects: 29
Study 34854816 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 29
Study 34854818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with the Pfizer vaccine
Number of subjects: 0
Study 34854818 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental analysis of innate immune response
Number of subjects: 0
Study 34854818 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological analysis of vaccination history
Number of subjects: 0
Study 34854818 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical analysis of immunological profile
Number of subjects: 0
Study 34854918 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized clinical care pathway
Number of subjects: 203
Study 34855038 — intervention group
Group type: EXPERIMENTAL
Intervention: Near Vision Presbyopia Task-based Questionnaire (NVPTQ)
Number of subjects: 20
Study 34855038 — intervention group
Group type: EXPERIMENTAL
Intervention: NVPTQ domain scores
Number of subjects: 20
Study 34855038 — intervention group
Group type: EXPERIMENTAL
Intervention: NVPTQ Performance and Satisfaction domain scores
Number of subjects: 20
Study 34855461 — intervention group
Group type: EXPERIMENTAL
Intervention: CD123 expression quartile 4 (Q4)
Number of subjects: 1040
Study 34855461 — intervention group
Group type: EXPERIMENTAL
Intervention: CD123 expression
Number of subjects: 1040
Study 34855461 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1040
Study 34855617 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging protocol incorporating narratives from Veterans
Number of subjects: 0
Study 34855617 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative messages, nonnarrative educational messages, and 2-way interactive messages
Number of subjects: 0
Study 34855617 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive text-messaging protocol
Number of subjects: 0
Study 34855617 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial underway
Number of subjects: 0
Study 34855619 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcome mobile app
Number of subjects: 0
Study 34855624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer COVID-19 convalescent plasma (>1:320 anti-spike IgG) transfusion
Number of subjects: 14
Study 34855624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer COVID-19 convalescent plasma transfusion
Number of subjects: 14
Study 34855649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline levels of social withdrawal
Number of subjects: 4461
Study 34855649 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychopharmacological treatment (12 weeks)
Number of subjects: 4461
Study 34855787 — intervention group
Group type: EXPERIMENTAL
Intervention: Homophobic victimization
Number of subjects: 747
Study 34856587 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 94
Study 34856587 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 94
Study 34856587 — intervention group
Group type: COMPARATOR
Intervention: Hospital costs for delayed surgery
Number of subjects: 94
Study 34857190 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention via an app
Number of subjects: 15
Study 34857190 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study 34857214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Iron Absorption Test (OIAT) combined with Oral Glucose Tolerance Test (OGTT) measuring ΔSeFe after an oral iron dose of 6 mg.
Number of subjects: 116
Study 34857214 — intervention group
Group type: COMPARATOR
Intervention: Fractional Iron Absorption (FIA) using stable iron isotopes from a labeled iron dose.
Number of subjects: 116
Study 34857214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Iron Absorption Test (OIAT)
Number of subjects: 116